Related Subjects:
|AIDS HIV
|Kaposi sarcoma (KS)
π About
- ποΈ Kaposi's sarcoma (KS) is a rare vascular malignancy, first seen in older men before the HIV era.
- 𧬠Now strongly associated with HIV infection and Human Herpesvirus 8 (HHV8).
- Common sites: skin, mucosa, lungs, GI tract, and lymph nodes.
𧬠Aetiology
- Caused by HHV8 infection in immunocompromised patients (especially with HIV).
- β¬οΈ More common in patients with advanced HIV/AIDS or iatrogenic immunosuppression (e.g., post-transplant).
- Sexual transmission of HHV8 is important in HIV-related cases.
βοΈ Pathophysiology
- Likely originates from endothelial cells.
- π Cytokine dysregulation β abnormal angiogenesis and vascular proliferation.
π©Ί Clinical Features
- π£ Skin lesions: non-blanching, redβpurple patches/plaques/nodules; often painless but may ulcerate; typically multifocal.
- π Mucosal lesions: common in the mouth, nose, or pharynx.
- π« Pulmonary involvement: haemoptysis, cough, chest pain, pleural effusion.
- π½οΈ GI involvement: dysphagia, abdominal pain, obstruction, weight loss.
- π§Ύ Systemic: fever, lymphadenopathy, diarrhoea, wasting in advanced disease.
π’ Forms of Kaposiβs Sarcoma
- π HIV-related (epidemic): most common, aggressive, linked to AIDS.
- π Iatrogenic: post-transplant immunosuppression.
- π΄ Classic (sporadic): elderly men (Mediterranean/Jewish/Eastern European); slow progression.
- π΄ Endemic (African): children/young adults in equatorial Africa; often aggressive.
π§Ύ Differential Diagnosis
- π¬ Bacillary angiomatosis (Bartonella) β biopsy & treat with antibiotics.
π Investigations
- π§ͺ Skin biopsy = gold standard.
- π FBC, U&E, ESR for baseline health.
- π« CXR/CT for pulmonary involvement.
- 𧬠HIV testing (if status unknown).
βοΈ Systemic Management
- π HAART β cornerstone in HIV-related KS; often leads to regression.
- β¬οΈ Reduce immunosuppression in transplant patients if possible.
- π Chemotherapy (e.g., liposomal doxorubicin) for extensive/systemic disease.
- π΄ In classic KS, conservative management may be reasonable unless complications arise (e.g., leg swelling β compression therapy).
π― Treating Symptomatic Lesions
- π Radiotherapy: useful for individual lesions.
- βοΈ Cryotherapy: liquid nitrogen for small lesions.
- π‘ Laser therapy: reduces pigmentation or lesion bulk.
- βοΈ Photodynamic therapy: topical light-sensitiser + light exposure.
- βοΈ Surgery: excision/curettage of isolated lesions.
- π Intralesional therapy: immune-modulating agents injected directly.
- π§΄ Topical retinoids for cutaneous lesions.
- π¨ Camouflage creams for cosmetic support post-treatment.
π‘ Exam tip:
Think KS in an HIV+ patient with purplish, non-blanching skin or oral lesions.
Always distinguish from Bacillary angiomatosis (infective, antibiotic-responsive).